Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Sotagliflozin in Hepatic Impairment
NCT02471274Phase 1Completed
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Jun 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sotagliflozin in type 1 diabetes mellitus (T1D), type 2 diabetes mellitus (T2DM) and heart failure (HF) (4 arms), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoint: Plasma concentration of sotagliflozin. Started Jun 2015; status: completed.
02
Drugs
sotagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)heart failure (HF)
Beyond the preview
Go deeper on NCT02471274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02471274.